# Summary of risk management plan for Dexmedetomidine Accord 100 micrograms/ml concentrate for solution for infusion (Dexmedetomidine hydrochloride)

This is a summary of the risk management plan (RMP) for dexmedetomidine Accord 100 micrograms/ml concentrate for solution for infusion. The RMP details important risks of dexmedetomidine Accord 100 micrograms/ml concentrate for solution for infusion, how these risks can be minimised, and how more information will be obtained about dexmedetomidine Accord 100 micrograms/ml concentrate for solution for infusion's risks and uncertainties (missing information).

Dexmedetomidine Accord 100 micrograms/ml concentrate for solution for infusion's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how dexmedetomidine Accord 100 micrograms/ml concentrate for solution for infusion should be used.

This summary of the RMP for Dexmedetomidine Accord 100 micrograms/ml concentrate for solution for infusion should be read in the context of all this information including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR).

Important new concerns or changes to the current ones will be included in updates of dexmedetomidine Accord 100 micrograms/ml concentrate for solution for infusion's RMP.

## I. The medicine and what it is used for

Dexmedetomidine Accord 100 micrograms/ml concentrate for solution for infusion is indicated

- for sedation of adult ICU (Intensive Care Unit) patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale (RASS) 0 to -3).
- for sedation of non-intubated adult patients prior to and/or during diagnostic or surgical procedures requiring sedation, i.e. procedural/awake sedation.

Further information about the evaluation of Dexmedetomidine Accord 100 micrograms/ml concentrate for solution for infusion's benefits can be found in Dexmedetomidine Accord 100 micrograms/ml concentrate for solution for infusion's EPAR, including in its plain-language

summary, available on the EMA website, under the medicine's webpage: https://www.ema.europa.eu/en/medicines/human/EPAR/dexmedetomidine-accord .

## II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of dexmedetomidine Accord 100 micrograms/ml concentrate for solution for infusion together with measures to minimise such risks and the proposed studies for learning more about dexmedetomidine Accord 100 micrograms/ml concentrate for solution for infusion risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size - the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status - the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In the case of Dexmedetomidine Accord 100 micrograms/ml concentrate for solution for infusion, these measures are supplemented with additional risk minimisation measures mentioned under relevant important risks, below.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

If important information that may affect the safe use of dexmedetomidine Accord 100 micrograms/ml concentrate for solution for infusion is not yet available, it is listed under 'missing information' below.

### II.A List of important risks and missing information

Important risks of dexmedetomidine Accord 100 micrograms/ml concentrate for solution for infusion are risks that need special risk management activities to further investigate or minimise

the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of dexmedetomidine Accord 100 micrograms/ml concentrate for solution for infusion. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

| | |
|---|---|
| Important identified risk (s) | • Atrioventricular block<br>• Cardiac arrest<br>• Bradycardia<br>• Hypotension<br>• Hypertension<br>• Hyperglycaemia<br>• Withdrawal syndrome |
| Important potential risk (s) | • Cortisol suppression<br>• Convulsions<br>• Hypothermia<br>• Torsade de pointes/QT prolongation<br>• Overdose<br>• Off-label use<br>• Increased mortality in younger ICU patients<br>• Rhabdomyolysis |
| Missing information | • Pregnancy |

## II.B Summary of important risks

| |
|---|
| **Atrioventricular block** |

| | |
|---|---|
| Risk minimisation measures | <u>Routine risk minimisation measures:</u><br>• SmPC sections 4.3, 4.4, 4.8<br>• PL sections 2, 4<br>• Contraindication of advanced heart block in section 4.3<br>• Advice that all patients should have continuous cardiac monitoring during Dexmedetomidine infusion included in section 4.4.<br>• Only available on prescription |
| **Cardiac arrest** | |
| Risk minimisation measures | <u>Routine risk minimisation measures:</u><br>• SmPC sections 4.4, 4.8, 4.9<br>• PL sections 2, 4<br>• Advice that all patients should have continuous cardiac monitoring during Dexmedetomidine infusion and advice on the length of monitoring when used in an outpatient setting included in section 4.4.<br>• Only available on prescription |
| **Bradycardia** | |
| Risk minimisation measures | <u>Routine risk minimisation measures:</u> |

| | |
|---|---|
| | • SmPC sections 4.2, 4.4, 4.5, 4.8, 4.9<br>• PL sections 2, 3, 4<br>• As described in section 4.2 patients should be continuously monitored for early signs of bradycardia.<br>• Advice that all patients should have continuous cardiac monitoring during Dexmedetomidine infusion included in section 4.4.<br>• Only available on prescription |
| **Hypotension** | |
| Risk minimisation measures | <u>Routine risk minimisation measures:</u><br>• SmPC sections 4.2, 4.3, 4.4, 4.5, 4.8, 4.9<br>• PL sections 2, 3, 4<br>• As described in section 4.2 patients should be continuously monitored for early signs of hypotension. The use of a loading dose during procedural sedation may increase the risk for hypotension in the elderly.<br>• Contraindication of uncontrolled hypotension in section 4.3<br>• Advice that all patients should have continuous cardiac monitoring during Dexmedetomidine infusion included in section 4.4.<br>• Only available on prescription |
| **Hypertension** | |
| Risk minimisation measures | <u>Routine risk minimisation measures:</u> |

| | |
|---|---|
| | • SmPC sections 4.2, 4.4, 4.8, 4.9<br>• PL sections 3, 4<br>• As described in section 4.2 patients should be continuously monitored for early signs of hypertension.<br>• Only available on prescription |
| **Hyperglycaemia** | |
| Risk minimisation measures | <u>Routine risk minimisation measures:</u><br>• SmPC section 4.8<br>• PL section 4<br>• Only available on prescription |
| **Withdrawal syndrome** | |
| Risk minimisation measures | <u>Routine risk minimisation measures:</u><br>• SmPC sections 4.4, 4.8<br>• PL section 4<br>• Only available on prescription |
| **Cortisol suppression** | |
| Risk minimisation measures | <u>Routine risk minimisation measures:</u><br>• SmPC section 5.1<br>• Only available on prescription |
| **Convulsions** | |
| Risk minimisation measures | <u>Routine risk minimisation measures:</u><br>• SmPC section 4.4<br>• Only available on prescription |
| **Hypothermia** | |

| | |
|---|---|
| Risk minimisation measures | <u>Routine risk minimisation measures:</u><br><br>None |
| **Torsade de pointes/QT prolongation** | |
| Risk minimisation measures | <u>Routine risk minimisation measures:</u><br><br>None |
| **Overdose** | |
| Risk minimisation measures | <u>Routine risk minimisation measures:</u><br><br>• SmPC sections 4.2, 4.9, 6.6<br>• Only available on prescription |
| **Off-label use** | |
| Risk minimisation measures | <u>Routine risk minimisation measures:</u><br><br>• SmPC sections 4.1, 4.2, 4.4<br>• PL sections 1, 3<br>• Indications and instructions for administration included in sections 4.1 and 4.2, respectively<br>• Use in only ICU, operating room and during diagnostic procedures emphasised in section 4.4.<br>• Only available on prescription |
| **Increased mortality in younger ICU patients** | |
| Risk minimisation measures | <u>Routine risk minimisation measures:</u><br><br>• SmPC section 4.4<br>• Section 4.4 where advice is given to weigh the findings of increased mortality in the age-group ≤65 years seen in the |

| | |
|---|---|
| | SPICE III trial against the expected clinical benefit of dexmedetomidine<br>• Only available on prescription<br><u>Additional risk minimisation measures:</u><br>• Direct Healthcare Professional Communication (DHPC) |
| **Rhabdomyolysis** | |
| Risk minimisation measures | <u>Routine risk minimisation measures:</u><br>None |
| **Pregnancy** | |
| Risk minimisation measures | <u>Routine risk minimisation measures:</u><br>• SmPC section 4.6<br>• PL sections 2<br>• Advice that Dexmedetomidine should not be used during pregnancy unless the clinical condition of the woman requires treatment with dexmedetomidine included in section 4.6.<br>• Only available on prescription |

## II.C Post-authorisation development plan

### II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of dexmedetomidine Accord 100 micrograms/ml concentrate for solution for infusion.

### II.C.2 Other studies in post-authorisation development plan

There are no studies required for dexmedetomidine Accord 100 micrograms/ml concentrate for solution for infusion.